Who
Jane Huang
Director
Company insider
Files Form 4 as: Director, Protara Therapeutics; President, CMO, Prelude Therapeutics; CMO, Hematology, BeOne Medicines.
In numbers
- Trades disclosed
- 345
- Buys
- 0
- Sells
- 56
- Bought
- $0
- Sold
- $39.8M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 2 Sep 2016
- Last trade
- 15 Jun 2026
- Last filed
- 16 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 16 Jun 2026 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 4 Oct 2025filed 7 Oct 2025 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,375 at $0.00 | filing |
| 4 Oct 2025filed 7 Oct 2025 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Code M | —9,375 | filing |
| 4 Oct 2025filed 7 Oct 2025 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Code F | $4,9323,355 at $1.47 | filing |
| 4 Jul 2025filed 8 Jul 2025 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,375 at $0.00 | filing |
| 4 Jul 2025filed 8 Jul 2025 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Code M | —9,375 | filing |
| 4 Jul 2025filed 8 Jul 2025 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,6503,355 at $0.79 | filing |
| 12 Jun 2025filed 13 Jun 2025 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 4 Apr 2025filed 7 Apr 2025 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,375 at $0.00 | filing |
| 4 Apr 2025filed 7 Apr 2025 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Code M | —9,375 | filing |
| 4 Apr 2025filed 7 Apr 2025 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,2813,355 at $0.68 | filing |
| 4 Feb 2025filed 5 Feb 2025 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 4 Jan 2025filed 7 Jan 2025 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,375 at $0.00 | filing |
| 4 Jan 2025filed 7 Jan 2025 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Code M | —9,375 | filing |
| 4 Jan 2025filed 7 Jan 2025 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Code F | $5,3643,859 at $1.39 | filing |
| 4 Oct 2024filed 7 Oct 2024 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,375 at $0.00 | filing |
| 4 Oct 2024filed 7 Oct 2024 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Code M | —9,375 | filing |
| 4 Oct 2024filed 7 Oct 2024 | PRLD Prelude TherapeuticsBiotechnology | SEC FORM 4 Code F | $6,6983,349 at $2.00 | filing |
| 4 Jul 2024filed 8 Jul 2024 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,375 at $0.00 | filing |
News
Reviewing Arbutus Biopharma (NASDAQ:ABUS) & Prelude Therapeutics (NASDAQ:PRLD)PRLD · tickerreport.com · 17 Oct 2026BeOne Medicines (NASDAQ:ONC) Price Target Raised to $420.00ONC · tickerreport.com · 10 Oct 2026
0 headlines in the last 90 days name Jane Huang; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.